These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 3019968)

  • 1. Human pharmacokinetics of WR-2721.
    Shaw LM; Turrisi AT; Glover DJ; Bonner HS; Norfleet AL; Weiler C; Kligerman MM
    Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1501-4. PubMed ID: 3019968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue levels of WR-1065, the active metabolite of amifostine (Ethyol), are equivalent following intravenous or subcutaneous administration in cynomolgus monkeys.
    Bachy CM; Fazenbaker CA; Kifle G; McCarthy MP; Cassatt DR
    Oncology; 2004; 67(3-4):187-93. PubMed ID: 15557777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of WR-1065 in mouse tissue following treatment with WR-2721.
    Utley JF; Seaver N; Newton GL; Fahey RC
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1525-8. PubMed ID: 6090355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alkaline phosphatase promotes radioprotection and accumulation of WR-1065 in V79-171 cells incubated in medium containing WR-2721.
    Calabro-Jones PM; Fahey RC; Smoluk GD; Ward JF
    Int J Radiat Biol Relat Stud Phys Chem Med; 1985 Jan; 47(1):23-7. PubMed ID: 2982751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uptake of WR-2721 derivatives by cells in culture: identification of the transported form of the drug.
    Calabro-Jones PM; Aguilera JA; Ward JF; Smoluk GD; Fahey RC
    Cancer Res; 1988 Jul; 48(13):3634-40. PubMed ID: 2837319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro metabolism of the phosphorothioate radioprotectors WR-2721 and WR-3689.
    Livesey JC; Rasey JS; Vertrees S; Freeman LM; Magee S; Nelson NJ; Chin L; Grunbaum Z; Krohn KA
    Pharmacol Ther; 1988; 39(1-3):215-7. PubMed ID: 2849127
    [No Abstract]   [Full Text] [Related]  

  • 7. Modification of WR-2721 toxicity and radioprotection by an inhibitor of alkaline phosphatase.
    Brown DQ; Shaw LM; Pittock JW; Mann DJ; Hardiman J; Pogach R; Gold J
    Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1491-3. PubMed ID: 3019966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variation in normal tissue responsiveness to WR-2721.
    Yuhas JM; Afzal SM; Afzal V
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1537-9. PubMed ID: 6090357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical studies on the radioprotective efficacy and pharmacokinetics of subcutaneously administered amifostine.
    Cassatt DR; Fazenbaker CA; Kifle G; Bachy CM
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):2-8. PubMed ID: 12577236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distribution of 35S-labeled WR-2721 in normal and malignant tissues of the mouse1,2.
    Utley JF; Marlowe C; Waddell WJ
    Radiat Res; 1976 Nov; 68(2):284-91. PubMed ID: 185642
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacokinetic profile of amifostine.
    Shaw LM; Bonner H; Lieberman R
    Semin Oncol; 1996 Aug; 23(4 Suppl 8):18-22. PubMed ID: 8783662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A method for the combined measurement of ethiofos and WR-1065 in plasma: application to pharmacokinetic experiments with ethiofos and its metabolites.
    Swynnerton NF; Huelle BK; Mangold DJ; Ludden TM
    Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1495-9. PubMed ID: 3019967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of amifostine and its metabolites in the plasma and ascites of a cancer patient.
    Korst AE; Gall HE; Vermorken JB; van der Vijgh WJ
    Cancer Chemother Pharmacol; 1996; 39(1-2):162-6. PubMed ID: 8995515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Possible association of radioprotective and chemoprotective aminophosphorothioate drug activity with polyamine oxidase susceptibility.
    Gaugas JM
    J Natl Cancer Inst; 1982 Aug; 69(2):329-32. PubMed ID: 6287074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein binding of N-2-mercaptoethyl-1,3-diaminopropane via mixed disulfide formation after oral administration of WR 2721.
    Tabachnik NF; Blackburn P; Peterson CM; Cerami A
    J Pharmacol Exp Ther; 1982 Feb; 220(2):243-6. PubMed ID: 6276531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of dose and schedule on the efficacy of ethyol: preclinical studies.
    Cassatt DR; Fazenbaker CA; Kifle G; Bachy CM
    Semin Oncol; 2003 Dec; 30(6 Suppl 18):31-9. PubMed ID: 14727238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the protective effects of three phosphorothioate radioprotectors in the RIF-1 tumor.
    Rasey JS; Krohn KA; Magee S; Nelson N; Chin L
    Radiat Res; 1986 Nov; 108(2):167-75. PubMed ID: 3024202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dephosphorylation of WR-2721 with mouse tissue homogenates.
    Mori T; Nikaido O; Sugahara T
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1529-31. PubMed ID: 6090356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Studies on the radioprotective effects of YM-08310 (= WR-2721) Part 1: Radioprotective effects of YM-08310 on normal and malignant tissues in mice].
    Tanaka Y; Akagi K; Hasegawa T; Nakazawa M; Harima K; Murata T; Sawada S
    Nihon Igaku Hoshasen Gakkai Zasshi; 1983 May; 43(5):700-9. PubMed ID: 6312407
    [No Abstract]   [Full Text] [Related]  

  • 20. Subcutaneous administration of amifostine (ethyol) is equivalent to intravenous administration in a rat mucositis model.
    Cassatt DR; Fazenbaker CA; Kifle G; Bachy CM
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):794-802. PubMed ID: 14529786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.